DKC1 and nonpapillary renal cell carcinoma: For 85 ccRCC patients treated with Sunitinib in the IMmotion 150 cohort, the DKC1-high group exhibited significantly increased TERC expression (high vs low, P = 0.014); however, a highly significant increase was seen in female (P = 0.0007) but not male (P = 0.18) patients (Fig. 5B).